妊娠期妇女维生素D补充方案。
完整摘要 · 中文译文
理由:妊娠期维生素D缺乏很常见,并与母婴不良健康结局相关,包括先兆子痫、妊娠期糖尿病、早产和低出生体重。世界卫生组织(WHO)建议妊娠期维生素D摄入量为每天200国际单位(IU)。对于疑似维生素D缺乏的妇女推荐补充维生素D,但并非普遍推荐。妊娠期不同剂量(方案)维生素D的效果尚未确定。这是2019年首次发表的Cochrane综述的更新版,该综述的结论是,补充维生素D(任何剂量)对母亲或新生儿结局可能几乎没有或没有有益影响。 目的:评估妊娠期不同剂量维生素D补充(单独或与钙或其他微量营养素联合)的效果:超过600 IU/天与高达600 IU/天,以及4000 IU/天或更多与低于4000 IU/天。 检索方法:我们于2026年4月检索了Cochrane对照试验中心注册库(CENTRAL)、ClinicalTrials.gov、WHO国际临床试验注册平台及相关数据库。 纳入标准:我们纳入评估妊娠期不同维生素D方案对母婴健康结局影响的随机试验。患有既往疾病或多胎妊娠的孕妇试验被排除。 结局:关键的母体结局是先兆子痫、妊娠期糖尿病和任何不良事件。 关键婴儿结局为早产和低出生体重。 偏倚风险:我们使用Cochrane RoB 1工具独立评估纳入研究的偏倚风险。 综合方法:两名综述作者独立评估研究资格并从纳入研究中提取数据。在合理假设各项研究估计相同的基础治疗效果时,我们在RevMan中进行了固定效应荟萃分析。若检测到实质性异质性,我们进行随机效应荟萃分析,二分类结局采用Mantel-Haenszel法,连续型结局采用逆方差法。我们使用GRADE方法评估证据的确定性。 纳入研究:本综述更新纳入了25项研究,共7008名孕妇。纳入研究于2004年至2024年间在14个国家开展。我们排除了29项研究,识别出23项正在进行的研究,并将21项研究列为待分类。 结果综合:25项纳入研究的总体偏倚风险为混合性。由于存在严重偏倚风险和研究结果的不精确性,大多数关键结局的证据确定性为低。维生素D剂量超过600 IU/天 versus 不超过600 IU/天,单独使用或与其他微量营养素联合使用(19项研究,5141名女性)妊娠期补充维生素D剂量超过600 IU/天,与不超过600 IU/天相比,对子痫前期风险可能几乎没有或没有差异(风险比(RR)0.90,95%置信区间(CI)0.65至1.25;8项研究,2629名女性;低确定性 低确定性证据)、妊娠期糖尿病(RR 0.85,95% CI 0.52至1.40;6项研究,2373名女性;低确定性证据)、早产(RR 1.02,95% CI 0.78至1.32;7项研究,3411名女性;低确定性证据)或低出生体重(RR 0.90,95% CI 0.71至1.14;6项研究,2090名女性;低确定性证据)。维生素D剂量4000 IU/天或以上对比低于4000 IU/天,单独使用或与其他微量营养素联合使用(14项研究,4954名女性)。妊娠期补充维生素D剂量为4000 IU/天或以上,与低于4000 IU/天相比,对子痫前期的风险可能几乎没有或没有差异(RR 0.90,95% CI 0.65至1.25;5项研究,2456名女性;低确定性证据)、妊娠期糖尿病(RR 0.86,95% CI 0.55至1.35;5项研究,2420名女性;低确定性证据)或早产(RR 0.97,95% CI 0.79至1.19;7项研究,3409名女性;低确定性证据),且对低出生体重的风险可能几乎没有或没有差异(RR 0.96,95% CI 0.76至1.21;3项研究,1637名女性;中等确定性证据)。两项比较中的不良事件。各研究报告不良事件(如高钙血症、维生素D过多症)的方式存在异质性。报告的不良事件较少,我们观察到组间无差异(低确定性至中等确定性证据)。 作者结论:妊娠期补充较高剂量对比较低剂量的维生素D对子痫前期、妊娠期糖尿病、早产或低出生体重的风险可能几乎没有或没有差异。未来研究应优先开展有足够把握度的试 采用统一研究设计的试验,纳入更多来自代表性不足地区的女性,并聚焦于一组定义一致的母婴健康结局。此外,试验应包含更长期的随访,以评估出生后婴儿和儿童的健康结局。 资助:本Cochrane综述无专项资助。 注册:本综述的上一版本于2019年发表(DOI 10.1002/14651858.CD013446)。本综述的原始方案已在PROSPERO注册(https://www.crd.york.ac.uk/PROSPERO/view/CRD42018103763)。
完整摘要 · 英文原文
RATIONALE: Vitamin D deficiency is common in pregnancy and has been associated with adverse health outcomes for the mother and infant, including pre-eclampsia, gestational diabetes, preterm birth, and low birthweight. The World Health Organization (WHO) recommends a vitamin D intake of 200 international units (IU) per day during pregnancy. Vitamin D supplementation is recommended for women with suspected vitamin D deficiency, but it is not universally recommended. The effects of different doses (regimens) of vitamin D during pregnancy have not been established. This is an update of a Cochrane review first published in 2019, which concluded that vitamin D supplementation (at any dose) may have little or no beneficial effects on maternal or neonatal outcomes. OBJECTIVES: To assess the effects of different doses of vitamin D supplementation (alone or in combination with calcium or other micronutrients) during pregnancy: more than 600 IU/day versus up to 600 IU/day, and 4000 IU/day or more versus less than 4000 IU/day. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, and relevant databases in April 2026. ELIGIBILITY CRITERIA: We included randomised trials evaluating the effects of different vitamin D regimens during pregnancy on maternal and infant health outcomes. Trials of pregnant women with pre-existing conditions or multiple pregnancies were excluded. OUTCOMES: The critical maternal outcomes were pre-eclampsia, gestational diabetes, and any adverse events. The critical infant outcomes were preterm birth and low birthweight. RISK OF BIAS: We used the Cochrane RoB 1 tool to independently assess the risk of bias in included studies. SYNTHESIS METHODS: Two review authors independently assessed study eligibility and extracted data from included studies. We conducted fixed-effect meta-analyses in RevMan where it was reasonable to assume that studies were estimating the same underlying treatment effect. If substantial heterogeneity was detected, we conducted random-effects meta-analyses, using the Mantel-Haenszel method for dichotomous outcomes and inverse-variance method for continuous outcomes. We used the GRADE approach to assess the certainty of the evidence. INCLUDED STUDIES: This review update included 25 studies with 7008 pregnant women. The included studies were conducted in 14 countries between 2004 and 2024. We excluded 29 studies, identified 23 ongoing studies, and listed 21 studies as awaiting classification. SYNTHESIS OF RESULTS: The overall risk of bias of the 25 included studies was mixed. The certainty of the evidence was low for most critical outcomes due to serious risk of bias and imprecision in the results. Vitamin D at a dose of more than 600 IU/day versus up to 600 IU/day, alone or in combination with other micronutrients (19 studies, 5141 women) Vitamin D supplementation during pregnancy at doses of more than 600 IU/day, compared with up to 600 IU/day, may make little or no difference to the risk of pre-eclampsia (risk ratio (RR) 0.90, 95% confidence interval (CI) 0.65 to 1.25; 8 studies, 2629 women; low-certainty evidence), gestational diabetes (RR 0.85, 95% CI 0.52 to 1.40; 6 studies, 2373 women; low-certainty evidence), preterm birth (RR 1.02, 95% CI 0.78 to 1.32; 7 studies, 3411 women; low-certainty evidence), or low birthweight (RR 0.90, 95% CI 0.71 to 1.14; 6 studies, 2090 women; low-certainty evidence). Vitamin D at a dose of 4000 IU/day or more versus less than 4000 IU/day, alone or in combination with other micronutrients (14 studies, 4954 women) Vitamin D supplementation during pregnancy at doses of 4000 IU/day or more, compared with less than 4000 IU/day, may make little or no difference to the risk of pre-eclampsia (RR 0.90, 95% CI 0.65 to 1.25; 5 studies, 2456 women; low-certainty evidence), gestational diabetes (RR 0.86, 95% CI 0.55 to 1.35; 5 studies, 2420 women; low-certainty evidence), or preterm birth (RR 0.97, 95% CI 0.79 to 1.19; 7 studies, 3409 women; low-certainty evidence), and probably makes little or no difference to the risk of low birthweight (RR 0.96, 95% CI 0.76 to 1.21; 3 studies, 1637 women; moderate-certainty evidence). Adverse events in both comparisons Reporting of adverse events (e.g. hypercalcaemia, hypervitaminosis D) was heterogeneous across studies. Few adverse events were reported, and we observed no differences between groups (low-certainty to moderate-certainty evidence). AUTHORS' CONCLUSIONS: Vitamin D supplementation during pregnancy at higher versus lower doses may make little or no difference to the risk of pre-eclampsia, gestational diabetes, preterm birth, or low birthweight. Future research should prioritise adequately powered trials with harmonised study designs that include more women from under-represented regions and focus on a consistently defined set of maternal and infant health outcomes. Additionally, trials should include longer follow-up to assess infant and child health outcomes beyond birth. FUNDING: This Cochrane review had no dedicated funding. REGISTRATION: The previous version of this review was published in 2019 (DOI 10.1002/14651858.CD013446). The original protocol for this review was registered with PROSPERO (https://www.crd.york.ac.uk/PROSPERO/view/CRD42018103763).